Pcsk9 monoclonal antibodies: new developments and their relevance in a nucleic acid-based therapy era

HIGHLIGHTS

• who: Ioanna Gouni-Berthold from the Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str62, Cologne, Germany have published the research work: PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid-Based Therapy Era, in the Journal: (JOURNAL)

SUMMARY

Thus increasing the serum levels of LDL cholesterol (LDL-C). PCSK9 monoclonal_antibodies (PCSK9-mAb) decrease LDL-C by inhibiting circulating PCSK9 and therefore promoting the recycling of the LDL receptor in the cell surface. During the last couple of years, new . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.